In addition to cardiovascular testing for clinical trials, BioTel Research offers full-service imaging capabilities. Supporting all major areas of drug and device research imaging, we offer a complete suite of services, using an efficient database infrastructure that is Part 11 FDA-compliant and always accessible. Our team includes board-certified radiologists, sub-specialty experts, thought leaders, and highly trained technicians who are dedicated to help design and implement the optimal protocol to acquire, evaluate, and transfer accurate, high-quality data through an efficient, cost-effective, and state-of-the-art global infrastructure.
The pipeline of potential cancer treatments continues to expand, resulting in an increasing number of clinical trials utilizing imaging. Whether a trial is assessing longest diameter, sum of the products of diameters (SPD), tumor volume, or other oncology endpoints, the imaging core lab at BioTel Research analyzes imaging data and delivers structural and volumetric measurements for a variety of oncology/hematology assessment criteria and all oncology/hematology imaging modalities. For hematological disorders such as leukemia and lymphoma, we can provide standard assessments such as measuring changes in lymph nodes or organomegaly using CT scans and can execute more complex protocols such as measurements of tumor metabolism (FDG-PET), tumor cell proliferation (FLT-PET), tumor perfusion/vessel permeability (DCE-MRI) and tumor density/integrity (DW-MRI). Additionally, our scientific and medical teams will work with you to implement modifications to published criteria as well as provide specialized assessments of other structural or functional parameters utilizing custom algorithms to provide robust and reliable solutions.
BioTel Research is an imaging core lab with vast experience in echocardiography (ECHO) and maintains a state-of-the-art ECHO processing infrastructure. Experienced physicians perform all ECHO analyses, including quantification of cardiac chamber size, ventricular mass, cardiac function, volume, and wall thickness. Display modes include 2-D, M-Mode, Doppler, and Tissue Doppler. These procedures are based on the American Society for Echocardiography guidelines, which are widely applied to clinical research and clinical practice. Our comprehensive list of modalities in cardiovascular imaging includes:
Our imaging core lab provides quantitative imaging analysis for metabolic disorders such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Our metabolic endpoint measurements include hepatic fat fraction, hepatic fibrosis, hepatic iron content, liver and spleen volume, abdominal subcutaneous adipose tissue (ASAT) volume, and visceral adipose tissue (VAT) volume as well as body composition measurements from DXA.
Our imaging core lab offering includes density, T-score, Z-score, and other standard endpoints. For arthritis, measurements include scoring as well as quantitative and cartilage/bone endpoints.
BioTel Research consistently delivers imaging solutions for a wide variety of central and peripheral nervous system diseases, including Alzheimer’s disease, multiple sclerosis, and tuberous sclerosis. Whether your trial requires standard assessments such as brain volume, hippocampal atrophy, white matter lesion measurement, or more complex functional or molecular imaging assays, the right imaging solution for your trial will be determined by leveraging our scientific and medical teams’ experience and expertise.
© 2022 BioTelemetry, a Philips Company. All rights reserved
